The Serum Level of Insulin Growth Factor-1 and Insulin Growth Factor Binding Protein-3 in Children with Henoch-Schönlein Purpura.
10.3339/jkspn.2016.20.1.23
- Author:
Hee Jin KIM
1
;
Su Jin JUNG
;
Jun Ho LEE
Author Information
1. Department of Pediatrics, CHA Bundang Medical Center, CHA University, Seongnam, South Korea. naesusana@gmail.com jinped@hanmail.com
- Publication Type:Original Article
- Keywords:
Insulin growth factor-1;
Insulin growth factor binding protein-3;
Henoch Schönlein purpura
- MeSH:
Antibodies, Antineutrophil Cytoplasmic;
Blood Sedimentation;
Child*;
Complement C3;
Endocrinology;
Hematologic Tests;
Humans;
Immunoglobulin A;
Insulin*;
Insulin-Like Growth Factor Binding Protein 3;
Insulin-Like Growth Factor I;
Leukocyte Count;
Logistic Models;
Nephritis;
Outpatients;
Platelet Count;
Purpura*
- From:Childhood Kidney Diseases
2016;20(1):23-28
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We investigated whether serum levels of insulin growth factor-1 (IGF-1) and insulin growth factor binding protein-3 (IGFBP-3) are valuable in predicting clinical outcomes or are correlated with other laboratory findings in children with Henoch-Schönlein purpura (HSP). METHODS: We examined 27 children who were consecutively admitted to our hospital with HSP between January 2011 and February 2012. Blood tests (C-reactive protein, white blood cell count, platelet count, erythrocyte sedimentation rate, albumin, immunoglobulin A, complement C3, antineutrophil cytoplasmic antibody, IGF-1, IGFBP-3) and urine tests were performed upon admission. IGF-1 and IGFBP-3 were resampled in the recovery phase. Controls included 473 children whose IGF-1 and IGFBP-3 were sampled for evaluating their growth, at the outpatient department of pediatric endocrinology in our hospital. IGF-1 and IGFBP-3 were compared between the HSP children and controls, and between the acute and recovery phases in HSP children. The ability of these values to predict clinical outcomes including renal involvement was analyzed using bivariate logistic regression analysis (BLRA). RESULTS: IGF-1 and IGFBP-3 were not different between the HSP children and controls (148.7±117.6 vs. 69.2±96.9, P=0.290: 3465.9±1290.9 vs. 3597.2±1,127.6, P=0.560, respectively). There was no significant difference in IGF-1 or IGFBP-3 between acute and recovery phases. Based on the BLRA, no variable, including IGF-1 and IGFBP-3, could predict clinical outcomes including the presence of nephritis. CONCLUSION: We concluded that IGF-1 and IGFBP-3 do not predict clinical outcomes of HSP, including renal involvement, in this study.
